EFMC-ISMC 2022

XXVII EFMC International Symposium on Medicinal Chemistry

 Nice, France    September 4-8, 2022

EFMC Award Lectures

Prof. Alessio CIULLI
Prous Institute - Overton and Meyer Award for New Technologies in Drug Discovery
Award Lecture
Prof. Herbert WALDMANN
Nauta Pharmacochemistry Award for Medicinal Chemistry and Chemical Biology
Award Lecture
Prof. Mike WARING
UCB Ehrlich Award for Excellence in Medicinal Chemistry
Award Lecture

Plenary Speakers

Prof. Benoit DEPREZ
Discovery of Lead Compounds and Drug Candidates : Opportunities Unique to the World of Small Molecules
Prof. Eric MISKA
New Biology and Therapeutic Approaches from RNA Shape and Modification
Prof. Sarah E. REISMAN
Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire
Prof. Outi VAARALA
Title to be announced
 
 

Invited Speakers

Dr Louise WALPORT
De Novo Cyclic Peptides as Chemical Tools to Explore Epigenetic Regulation
Dr Karine ALVAREZ
Current Challenges in Antiviral Therapies Against Coronaviruses and Other Emerging RNA Viruses
Prof. Michelle ARKIN
Fragment-Based Approaches to Stabilize Protein-Protein Interactions
Dr Andrea BECCARI
Embrace Complexity: in Silico Polypharmacological Profiling to Repurpose Medicines and Design New Drugs
Dr Amy BITTNER MCCRACKEN
Inhibiting the MYC Oncogene through Cell Active Max-E47 (ME-47)
Prof. Jeffrey BODE
Molecular Vending Machines for the On-Demand Synthesis of Drug-Like Molecules
Prof. Pascal BONNET
Discovery of Novel Kinase Inhibitors Through in Silico Fragment-Based Ligand Screening
Dr Marco BORGOGNO
Discovery of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Autism, Down Syndrome, and Brain Disorders with Defective NKCC1/KCC2 Ratio
Dr Andreas BRUNSCHWEIGER
A DNA Barcode with Enhanced Chemical Stability for DNA-encoded Library Design
Prof. Youngjoo BYUN
Medicinal Chemistry in the Development of Molecular Imaging Probes Targeting Prostate-Specific Membrane Antigen
Dr Sébastien CAMPAGNE
Fundamental Basis for SMN2 Specific Splicing Correction by Small Molecules and Bulge Repair Mechanism
Dr Lisa CANDISH
Photocatalysis in Drug Discovery
Prof. Connor COLEY
A Perspective on AI and Automation for the Medicinal Chemistry Lab
Dr Michael J. DART
eIF2B Activators Beyond ISRIB: New Integrated Stress Response Inhibitors
Dr David DAVIES
Discovery of ANT3310, a Novel Broad-Spectrum Serine β Lactamase Inhibitor of the Diazabicyclooctane Class, which strongly Potentiates Meropenem Activity against Carbapenem-Resistant Enterobacterales and Acinetobacter Baumannii
Prof. Charlotte DEANE
The Power and Pitfalls of Machine Learning in Early Stage Drug Discovery
Dr Lourdes ENCINAS
Novel Tetrazole Inhibitor of Mycobacterium Tuberculosis Tryptophan Synthase
Mr Lluc FARRERA SOLER
EFMC-YMCS Prize 2021
A Mating Mechanism to Generate Diversity for the Darwinian Selection of DNA-encoded Synthetic Molecules
Dr Yann FORICHER
Targeting RNA with Small Molecules, A New Therapeutic Strategy
Dr David FREEMAN
Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/Cyclin T1 for MYC-Dependent Cancers
Dr Marta FRIGOLE-VIVAS
Leveraging Biomolecular Condensates for Drug Discovery
Prof. Tanja GAICH
Title to be announced
Dr Amanda GARNER
Enabling Technologies for Revealing Druggable Paths in RNA Biology
Prof. Matthew GAUNT
Title to be announced
Prof. Matthias GEHRINGER
Discovery of Covalent Protein Kinase Inhibitors
Dr Carmen GIL
Searching for Drugs against Pandemic Viruses. A Case Study
Dr Darren GREEN
Automating Lead Optimisation with BRADSHAW
Prof. Gyorgy KESERU
Covalent Fragment Approaches in Drug Discovery
Prof. Angela KOEHLER
Attenuating Oncogenic Transcription with Small Molecules
Dr Sanja KOSTRUN
Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction
Dr Brian LANMAN
Inhibiting KRAS: Strategies, Structures, and Lessons Learned in the Invention of Sotorasib
Dr María MANEIRO
Antibody-Protac Conjugates: an Approach for Targeted Selective BRD4 Degradation in HER2+ Phenotypes
Dr Cristina MAYOR-RUIZ
Strategies to Discover Molecular Glue Degraders at Scale
Dr Hannes MIKULA
Next-level Chemical Tools for Ultrafast Bioorthogonal Bond-Cleavage Reactions
Dr Dieter MURI
Late Stage Tritiation of Drug- and PET-Tracer-Candidates
Dr Gerhard MÜLLER
The Phosphatase Family: a Widely Neglected Target Space for Small-Molecule Drug Discovery
Dr Frank NARJES
The discovery of the Clinical Candidate AZD0284, a Novel Orally Bioavailable Inverse Agonist of RORγ for the Treatment of Psoriasis
Prof. Zaneta NIKOLOVSKA-COLESKA
Disrupting hDot1L and MLL fusion protein interactions as a novel therapeutic strategy
Prof. Defang OUYANG
Opportunity and Challenge of Artificial Intelligence (AI) in Drug Delivery
Dr Alex PAUTSCH
Chemical Probes and How to Find Them
Prof. Jianfeng PEI
De Novo Drug Design Using 3D Deep Generative Models
Prof. Laura PIDDOCK
The Global Antibiotic R&D Partnership: Helping to Advance the Discovery & Development of New Treatments for Bacterial Infections
Prof. William POMERANTZ
New Opportunities for Studying the Function of the Nucleosome Remodeling Factor NURF Through Chemical Inhibition and Degradation
Prof. Eugen PROSCHAK
Chemical Probes for Targets in Lipid Signalling
Dr Renaud PRUDENT
EDELRIS Keymical Space™ and GPCR : Identification of Allosteric Binders by AS-MS
Dr Jean QUANCARD
Tipping the Balance: MALT1 Inhibitors with Paradoxical Effects on the Immune System
Prof. Fraydoon RASTINEJAD
Transcription Factors as Drug-Discovery Targets
Prof. Andrea RENTMEISTER
Enzymatic Photocaging of Nucleic Acids: A Strategy for Controlling Methyltransferase Target Sites by Light
Dr Marc ROBILLARD
Title to be announced
Prof. Judith ROLLINGER
Big Data Analyses for the Discovery of Lead Structures from Nature
Dr Fanny ROUSSI
Design of Naturally Inspired Anti-Cancer Compounds that Modulate Cholesterol Homeostasis
Dr Jörg SCHEUERMANN
New Aspects in DNA-encoded Chemical Library Construction and Screening
Prof. Roger SCHIBLI
Radiotheragnostics from Bench-to-Bedside
Prof. Wenqing SHUI
Title to be announced
Prof. Kristian STROMGAARD
Targeting Protein-Protein Interactions of Receptor Complexes
Dr Nicolas THOMÄ
Title to be announced
Prof. Guy VAN DEN MOOTER
Title to be announced
Mr Jarrod WALSH
High Throughput Affinity Screening for Rapid Hit Discovery and Prosecuting Intractable Targets
Prof. Daniel Martin WATTERSON
Exploring Alternative Targets and Development of Precision Medicine Tools for CNS Diseases
Prof. Feng ZHU
Title to be announced

Oral Communication

Dr Bauke ALBADA
Chemical Modification of Wild-type Proteins
Dr Paola B. ARIMONDO
Antidotes for Diseases: Chemistry and Biology Match Together to Tackle Epigenetics\R\N\R\N
Dr Giulia BERGONZINI
Visible-light Photocatalysis: a Powerful Tool in the Pursuit of New Pharmaceuticals
Dr Virgyl CAMBERLEIN
Discovery of Pseudomonas Aeruginosa Elastase LasB Inhibitors by in Situ Click Chemistry
Ms Laura CARZANIGA
Discovery of Clinical Candidate CHF-6366: a Super-soft Heterobifunctional Muscarinic Antagonist and β2-adrenoceptor Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases
Prof. Christina CHAI
Tuning the Reactivity of the Natural Product Andrographolide: Towards Targeted Covalent Inhibitors for the Treatment of Inflammation
Prof. Rebecca DEPREZ-POULAIN
First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation
Dr Richard DOVESTON
Molecular Glues for the 14-3-3 Interactome
Dr Herve GENESTE
In Silico Prediction of Brain Penetration - High Accuracy Achieved
Dr Francesco GRECO
NR2F6 Antagonists: in Vitro Pharmacology and Preclinical Data of a Potential Next Generation Immuno-oncology Therapy
Dr Gilles GUICHARD
Structure-Guided Design of Foldamer-Based Inhibitors of Protein-Protein Interactions
Dr Thomas HAYHOW
Discovery And Profiling of AZ-6421: an Oral ERa-Protac with an in vitro-in vivo Disconnect
Dr Timo HEINRICH
Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106
Prof. Roderick HUBBARD
Photoactivated Covalent Capture of DNA-encoded Fragments to Identify Ligands for Challenging Targets
Dr Soufyan JERHAOUI
Discovery of JNJ-1245, a Novel and Potent Fluoroallylamide Mcl-1 Inhibitor for the Treatment of Hematologic Malignancies
Dr Manuela JORG
Identification and Structure-activity Relationship Profiling of Positive Allosteric Modulators Targeting Muscarinic Acetylcholine Receptors
Dr Anna JUNKER
Development of First PET Tracers for the Imaging of CD73 Expression in Triple-negative Breast Cancer
Ms Elizabeth A. LOPES
Dual Inhibition of P53-MDM2/4 Interactions With Spiropyrazoline Oxindoles
Ms Katherine MACFARLANE
Exploiting DNA-encoded Library Technology for the Discovery of Novel Antibody Recruiting Molecules Against LOX-1
Prof. Ana MARTINEZ
Modulation of TDP-43-pathy by Brain Penetrant Protein Kinase Inhibitors, a New Hope for ALS and Related Disorders
Dr Exequiel PORTA
Mining the Leishmania Kinome
Dr Stefano SAINAS
Human Dihydroorotate Dehydrogenase Inhibitor MEDS443: a Magic Bullet Against Coronaviruses
Dr Matthew SEGALL
Using AI to Derive Valuable Insights from Drug Discovery Data
Dr Alice SOSIC
Bis-3-chloropiperidines Targeting TAR RNA as a Novel Strategy to Impair the HIV-1 Nucleocapsid Protein
Dr Boris VAUZEILLES
Fast Detection and Imaging of Hydrogen Peroxide with New Borinic Probes
Dr Anita WEGERT
A New Dual Mode of Action to Treat Pain - From Scratch to Pre-Clinical Candidate
Dr Erik WEIS
Iridium-catalyzed C-H Activation Methods for Late-stage Functionalization of Pharmaceuticals
Dr Birgit WILDING
Discovery of Novel Covalent, EGFR WT Sparing, HER2 Selective Inhibitors for the Treatment of Her2 Exon 20 Insertion Driven Tumours
 
 

First Time Disclosures

Dr Sophie BERTRAND
Discovery and Optimisation of Potent, Slow-dissociating Inhaled PI4KB Inhibitors
Dr Kenneth GRANBERG
Discovery of AZD5462, an Oral Agonist of the Relaxin Family Peptide Receptor 1 (RXFP1) for the Treatment of Cardiorenal Disease
Dr Uwe GRETHER
First Disclosure of Cannabinoid Receptor Type 2 Agonist Rg7774 – An Innovative Oral Treatment for Diabetic Retinopathy
Dr Peter HAEBEL
Discovery of BI 456906, a Novel Long-acting GCG/GLP-1 Receptor Dual Agonist for the Treatment of Patients With Obesity
Dr Roland PFAU
MPGES1 Inhibitors: First Time Disclosure of Clinical Candidate BI01029539 / GS-248
Dr Kai SCHIEMANN
First-time Disclosure of M1069, a Highly Selective Dual Inhibitor of Adenosine A2a/A2b Receptors With Improved Therapeutic Activity Compared to A2a Receptor Selective Antagonists

EFMC Prizes for Young Medicinal Chemist or Chemical Biologist in Academia and in Industry
Ceremony & Lectures